Диссертация (1090330), страница 17
Текст из файла (страница 17)
P.58 – 61.62. Coffman, R.L. Vaccine adjuvants: putting innate immunity to work / R.L.Coffman, A. Sher, R. A. Seder // Immunity. – 2010. – V. 29. – P. 492-503.63. Cooper, P.D. Vaccine adjuvants based on gamma inulin / P.D.Cooper; In:M.F.Powell, M.J.Newman editors. Vaccine design: the subunit and adjuvant approach.New York: Plenum Press, 1995. – p. 559–580.64. Cooper, P.D. Vaccine adjuvants based on gamma inulin / P.D.Cooper // PharmBiotechnol. – 1995. – V.6.
– P. 559–580.65. Cooper, P.D. The adjuvanticity of algammulin, a new vaccine adjuvant /P.D.Cooper, C.McComb, E.J.Steele // Vaccine. – 1991. – V. 9. – P. 408–415.66. Cooper, P.D. Algammulin: a new vaccine adjuvant comprising gamma inulinparticles containing alum, preparation and in vitro properties / P.D.Cooper, E.J.Steele //Vaccine. – 1991. – V.9. – P. 351–357.67. Cornelie, S.
Direct evidence that toll-like receptor 9 (TLR9) functionally bindsplasmid DNA by specific cytosine-phosphate-guanine motif recognition / S.Cornelie,J.Hoebeke, A.M.Schacht, B.Bertin, J.Vicogne, M.Capron // J Biol Chem. – 2004. – V.279. – P. 15124–15129.68. Cornelie, S. Methylated CpG-containing plasmid activates the immune system/ S.Cornelie, O.Poulain-Godefroy, C.Lund, C.Vendeville, E.Ban, M.Capron // Scand JImmunol. 2004. – V.59.
– P.143–151.69. Cox, E. Adjuvants modulating mucosal immune responses or directingsystemic responses towards the mucosa / E.Cox, F.Verdonck, D.Vanrompay,B.Goddeeris // Vet Res. – 2006. – V. 37. – P. 511–539.12270. Davies, I.W. General Annulation Strategy for the Preparation of Pyridine NOxides / I.W.Davies, J.Marcoux, P.Reider // American Chemical Society. Org.
Lett. 3.2001. – V. 2. – P.209-211.71.Datta,S.K.Antigenimmunostimulatoryoligonucleotideconjugates:mechanisms and applications / S.K.Datta, H.J. Cho, K.Takabayashi, A.A.Horner, E.Raz// Immunol Rev. – 2004. – V.199. – P. 217–226.72. Dalsgaard, K. Adjuvants / K.Dalsgaard // Vet Immunol Immunopathol – 1987.– V. 17. – P.145 - 153.73. Dell, K. Intranasal immunization with human papillomavirus type 16capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increasedvaginal immunoglobulin levels / K.Dell, R.Koesters, M.Linnebacher, C.Klein,L.Gissmann // Vaccine. – 2006.
– V. 24. – P. 2238–2247.74. Egan, M.A. The use of cytokines and chemokines as genetic adjuvants forplasmid DNA vaccines / M.A.Egan, Z.R.Israel // Clin Appl Immunol Rev. – 2002. V. 2.– P. 255–287.75. Eldrige, J.H. Biodegradable and biocompatible poly (dl-lactide-co-glycolide)microspheres as an adjuvant for Staphylococcal enterotoxin B toxoid which enhances thelevel of toxin-neutralizing antibodies / J.H.Eldrige, J.K.Staas, J.A.Meulbroek // InfectImmun. – 1991. – V. 59. – P. 2978–2983.76. Eldrige, J.H.
Biodegradable microspheres as a vaccine delivery system / J.H.Eldrige, J.K.Staas, J.A.Meulbroek // Mol Immunol. – 1991. V. 28. – P. 287–290.77. European pharmacopoeia 7.5 Index, 2011.78. Falo, Jr L.D. Targeting antigen into the phagocytic pathway in vivo inducesprotective tumour immunity / Jr L.D.Falo, M. Kovacsovics-Bankowski, K.Thompson,K.L.Rock // Nat Med.
– 1995. – V.1. – P. 649–653.79. Fifis, T. Size-dependent immunogenicity: therapeutic and protective propertiesof nano-vaccines against tumors / T.Fifis, A.Gamvrellis, B.Crimeen-Irwin, G.A.Pietersz,J.Li, P.L.Mottram // J Immunol.
– 2004. – V. 173. – 3148–3154.80. Freestone, D.S. Antibody responses and resistance to challenge in volunteersvaccinated with live attenuaded detergent split and oil adjuvant A2/Hong Kong/68123(H3N2) influenza vaccines / D.S.Freestone, S.Hamilton-Smith, G.C.Schild, R.Buckland,S.Chinn, D.A.J.Tyrrel // J Hyg (Camb). – 1972. – V. 70. – P. 351–355.81. Freund, J. The mode of action immunological adjuvants / J.Freund // AdvTuberc Res.
– 1956. – V. 7. – 50–55.82. Galli, G. Adjuvanted H5N1 vaccine induces early CD4+ T cell response thatpredicts long-term persistence of protective antibody levels / G.Galli, D.Medini,E.Borgogni, L.Zedda, M.Bardelli, C.Malzone, S.Nuti, S.Tavarini, C.Sammicheli,A.K.Hilbert // Proc. Natl. Acad. Sci.
USA – 2009. – V. 106. – P. 3877- 3882.83. Galli, G. Fast rise of broadly cross-reactive antibodies after boosting long-livedhuman memory B cells primed by an MF59 adjuvanted prepandemic vaccine / G.Galli,K.Hancock, K.Hoschler, J.DeVos, M.Praus, M.Bardelli, C.Malzone, F.Castellino,C.Gentile, T.McNally // Proc. Natl. Acad. Sci. USA – 2009.
– V. 106. – P. 7962- 7967.84. Giannini, S.L. Enhanced humoral and memory B cellular immunity usingHPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination(AS04) compared to aluminium salt only / S.L.Giannini, E.Hanon, P.Moris, M.vanMechelen, S.Morel, F.Dessy // Vaccine. – 2006.
– V. 24. – P. 5937–5949.85. Glenny, A.T. The antigenic value of toxoid precipitated by potassium-alum /A.T.Glenny, C.G.Pope, H.Waddington, V.Wallace // J Path Bact. – 1926. – V. 29. – P.38- 45.86. Goto, N. Studies on the toxicities of aluminium hydroxide and calciumphosphate as immunological adjuvants for vaccines / N.Goto, H.Kato, J-I.Maeyama //Vaccine. – 1993. V. 11. – P.914–918.87. Gribble, G.W. Progress in Heterocyclic Chemistry vol.10 / G.W.Gribble,T.L.Gilchrist (eds.).
– London, N.Y: Pergamon, 1998. – 360p.88. Gribble, G.W. Progress in Heterocyclic Chemistry vol.11 / G.W.Gribble,T.L.Gilchrist (eds.). – London, N.Y: Pergamon, 1999. – 358p.89. Gribble, G.W. Progress in Heterocyclic Chemistry vol.12 / G.W.Gribble,T.L.Gilchrist (eds.). – London, N.Y: Pergamon, 2000.
– 376p.90. Gribble, G.W. Progress in Heterocyclic Chemistry vol.13 / G.W.Gribble,T.L.Gilchrist (eds.). – London, N.Y: Pergamon, 2001. – 400p.12491. Gribble, G.W. Progress in Heterocyclic Chemistry vol.14 / G.W.Gribble,T.L.Gilchrist (eds.). – London, N.Y: Pergamon, 2002. – 376p.92. Gribble, G.W. Progress in Heterocyclic Chemistry vol.15 / G.W.Gribble,T.L.Gilchrist (eds.). – London, N.Y: Pergamon, 2003. – 385p.93. Gribble, G.W. Progress in Heterocyclic Chemistry vol.21 / G.W.Gribble,T.L.Gilchrist (eds.). – London, N.Y: Elsevier, 2010. – 411p.94. Gribble, G.W.
Progress in Heterocyclic Chemistry vol.23 / G.W.Gribble,T.L.Gilchrist (eds.). – London, N.Y: Elsevier, 2011. – 387p.95. Gupta, R.K. Adjuvant properties of aluminium and calcium compounds.Vaccine design: the subunit and adjuvant approach / R.K.Gupta M.F. Powell, M.J.Newman, B.E. Rost, E. Relyveld, G.R.Siber // NewYork: Plenum Press – 1995. –P. 229- 248.96. Gupta, R.K. Adjuvant fot human vaccines-current status, problems and futureprospects / R.K. Gupta, G.R. Siber // Vaccine. – 1995. V.
13. – P. 1263–1270.97. Gursel, I. Repetitive elements in mammalian telomeres suppress bacterial DNAinduced immune activation / I.Gursel, M.Gursel, H.Yamada, K.J.Ishii, F.Takeshita,D.M.Klinman // J Immunol. – 2003. – V. 171. – P. 1393–1400.98. Harper, D.M. Efficacy of a bivalent L1 virus-like particle vaccine in preventionof infection with human papillomavirus types 16 and 18 in young women: a randomisedcontrolled trial / D.M.Harper, E.L.Franco, C.Wheeler, D.G.Ferris, D.Jenkins, A.Schuind// Lancet. – 2004. – V. 364. – 1757–1765.99.
Heath, T.D. The adjuvant properties of liposomes / T.D.Heath, D.C.Edwards,B.E.Ryman // Biochem Soc Trans. – 1976. – V. 4. – P. 49–52.100. Heufler, C. Granulocyte/macrophage colonystimulating factor and interleukin1 mediate the maturation of murine epidermal Langerhans cells into potentimmunostimulatory dendritic cells / C.Heufler, F.Koch, G.Schuler // J Exp Med.
– 1988.– V.167. – P. 700–705.101. Hilleman, M.R. Vaccines in historic evolution and perspective: a narrative ofvaccine discoveries / M.R. Hilleman// Vaccine. – 2000. – V.18. – P. 1436-1447.125102. Hilleman, M.R. Studies for safety of adjuvant 65 / M.R.Hilleman,A.F.Woodhour, A.Friedman, A.H.Phelps // Ann Allergy. – 1972. –V. 30. – P. 477–480.103. Hoebe, K.
The interface between innate and adaptive immunity / K.Hoebe,E.Janssen, B.Beutler // Nat. Immunol. – 2004. – V.5. – P. 971-974.104. Huleatt, J.W. Vaccination with recombinant fusion proteins incorporatingToll-like receptor ligands induces rapid cellular and humoral immunity / J.W.Huleatt,A.R.Jacobs, J.Tang, P.Desai, E.B.Kopp, Y.Huang, L.Song, V.Nakaar, T.J.Powell //Vaccine. – 2007.
– V. 25. – P. 763- 775.105. Jones, G.L. Peptide vaccine derived from a malarial surface antigen: effect ofdose and adjuvant on immunogenicity / G.L.Jones // Immunol Lett. – 1990. – V. 24. P.253–260.106. Katritzky, A.R. Six-membered Rings with One Heteroatom / A.R.Katritzky //Heterocyclic Chemistry III.
– 2008. – V. 7. Р. – .107. Katritzky, A.R. Chemistry of the Heterocyclic N-oxides / A.R.Katritzky,J.M.Lagowski. — London, N.Y.: Acad. Press, 1971. – 587p.108. Kensil, C.R. Saponins as vaccine adjuvants / C.R. Kensil // Crit Rev TherDrug Carrier Syst – 1996. – V. 13. – P. 1- 55.109. Kensil, C.R. Separation and characterization of saponins with adjuvantactivity from Quillaja saponaria Molina cortex / C.R. Kensil, U. Patel, M. Lennick, D.Marciani // J Immunol. –1991. – V. 146.
– P. 431–437.110. Kensil, C.R. Structural and immunological characterization of the vaccineadjuvant QS-21 / J-Y. Wu, S. Soltysik, Vaccine design: the subunit and adjuvantapproach. – New York: Plenum Press, 1995. С. 525–541.111. Khurana, S. Vaccines with MF59 adjuvant expand the antibody repertoire totarget protective sites of pandemic avian H5N1 influenza virus / S. Khurana, W.Chearwae, F.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
